Abstract: Prostate disorders are one of the main causes of quality of life disorders in men. Since 1994, the total PSA value has been approved by the United States Food and Drug Administration (FDA) as a marker of early detection, determining the stage and prognosis in prostate cancer. Many studies have reported the benefits of tumor-infiltrating lymphocytes (TILs) in tumor cells, where TILs are effective in slowing tumor progression, although the mechanism is still the opposite.